Zydus Cadila got approval from USFDA to market Fingolimod capsules 0.25 mg, for treatment of multiple sclerosis. Cadila is already USFDA approved 0.5 mg strength. Fingolimod treats relapsing forms of multiple sclerosis. Zydus is expected to manufacture the drug at its Ahmedabad SEZ facility. Zydus group now has filed 400 ANDAs and has 319 approvals.
Zydus Cadila got approval from USFDA to market Fingolimod capsules 0.25 mg, for treatment of multiple sclerosis. Cadila is already USFDA approved 0.5 mg strength. Fingolimod treats relapsing forms of multiple sclerosis. Zydus is expected to manufacture the drug at its Ahmedabad SEZ facility. Zydus group now has filed 400 ANDAs and has 319 approvals.